Board of Directors
Our board is composed of the following investors and industry executives:
Richard Heyman, Ph.D.
Dr. Heyman has over 25 years of biopharma experience. He previously served as CEO of Seragon Pharmaceuticals, a company focused on drugs targeting hormone dependent cancers acquired by the Roche Group, as co-founder and CEO of Aragon Pharmaceuticals, purchased by Johnson & Johnson in 2013, as co-founder and Chief Scientific Officer of X-Ceptor Therapeutics, and as Vice President of Research at Ligand Pharmaceuticals. At Ligand he led the development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer. He is the author or inventor on more than 120 publications and patents. In addition to serving on the Board of Directors for ORIC, Dr. Heyman also serves on the Board of Directors for Gritstone Oncology, Yumanity Therapeutics, Metacrine Inc , Vividion Therapeutics and Mavu Pharma. He is also the Vice Chairman of The Salk Institute. He was a NIH postdoctoral fellow at the Salk Institute, and received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut..
Managing Partner and Founder, The Column Group
Peter Svennilson is a Managing Partner and Founder of The Column Group, a biotech venture capital firm based in San Francisco. He has 30 years of experience in corporate finance, investment banking, and venture capital. He was the founder and a partner of Three Crowns Capital, a leading backer of a new generation of US biotechnology companies. He helped found companies such as Rosetta, PTC, Tercica, and Somalogic. Over the past 12 years he has helped finance and develop biotech companies, including Tularik, Sunesis, Chemocentryx, Infinity, AVEO, Rinat, and FivePrime. He is currently a Board Director of NGM Biopharmaceuticals, Immune Design, and Gritstone and has served on the Boards of several other biotechnology companies, including Seragon Pharmaceuticals (Chairman), Aragon Pharmaceuticals (Chairman), Rosetta, Somalogic, and ChemoCentryx. Before founding Three Crowns Capital, he was the Associate Managing Director of European Investment Banking Origination at Nomura Securities in London. He is currently a trustee for the Institute for Advanced Study in Princeton, New Jersey.
Richard Scheller, Ph.D.
CSO and Head of Therapeutic Development, 23andMe
Dr. Scheller is the chief scientific officer and head of therapeutic development at 23andMe. Dr. Scheller was previously the chief scientific officer at Genentech, and following the company’s merger with Roche, executive vice president and head of Genentech research and early development on Roche’s corporate executive committee. Prior to joining Genentech, Dr. Scheller was a professor at Stanford University and an investigator with the Howard Hughes Medical Institute at Stanford University Medical Center. His work has been recognized by the Albert Lasker Basic Medical Research Award, the Kavli Prize in Neuroscience, and the 1997 US National Academy of Sciences Award in Molecular Biology, among other honors, and he is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He serves as a trustee of Caltech and on the board of Xenon Pharmaceuticals Inc. He completed his post-doctoral studies at Caltech and the Columbia University College of Physicians and Surgeons. He received his Ph.D. in chemistry from Caltech and his B.S. from University of Wisconsin-Madison.
Carl L. Gordon, Ph.D., CFA
Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was at Fellow at The Rockefeller University from 1993 to 1995. Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.
Leo A. Guthart
Leo A. Guthart currently manages Topspin Biotech Fund, Topspin Partners, with principal focus on biotechnology, computer security and rechargeable batteries for electric vehicles and Topspin Partners LBO, a buyout fund. The funds are investing approximately $700 million.
He served as a Director of Aragon Pharmaceuticals (sold to Johnson & Johnson) and Seragon Pharmaceuticals (sold to Roche-Genentech). He is presently a Director of Peloton Pharmaceuticals.
He is a graduate of Harvard College where he received a BA degree in Physics and of Harvard Business School where he was a George F. Baker Scholar and received both an MBA and a Doctorate in Business Administration with a specialty in Corporate Finance. Mr. Guthart served on the faculty of Harvard Business School and was a Ford Foundation Fellow performing research on corporate share repurchases. His articles on share repurchases have been published in the Harvard Business Review, the Financial Analysts Journal and the Journal of Finance.
He serves as Treasurer of Cold Spring Harbor Laboratory and is a member of its Executive Committee, an Overseer of the Hofstra-NSLIJ Medical School and a Trustee Emeritus of the Stony Brook Foundation.
He was inducted into the Long Island Technology Hall of Fame. He was a Founding Director of the Long Island Research Institute.
Jacob Chacko, MD
Chief Executive Officer
Dr. Chacko was most recently CFO of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche in February 2018. At Ignyta, he had a broad operational role and helped raise over $500 million in capital. During his tenure, the company grew from fewer than 20 employees and a $50 million enterprise value to 125 employees and a $1.7 billion enterprise value at the time of acquisition. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital, where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion. He has served on the board of directors of RentPath and EnvisionRx and was a board observer to Par Pharmaceutical, IMS Health and Quintiles Transnational. He previously served on the board of the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford.
Dr. Chacko concurrently received his M.D. with AOA honors from UCLA and his M.B.A. with Distinction from Harvard Business School. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company. He received a M.Sc. from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the University Valedictorian. He currently serves on the board of directors of Bonti and AROG Pharmaceuticals and chairs the Western Regional Selection Committee for the Marshall Scholarship.